Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diseases of the Thyroid

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 15 articles:
HTML format



Single Articles


    July 2021
  1. ZHENG X, Xu Z, Ji Q, Ge M, et al
    A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0761.
    PubMed     Abstract available


  2. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    PubMed     Abstract available


    June 2021
  3. PAPPA T, Ahmadi S, Marqusee E, Johnson HL, et al
    Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF(V600E)-driven papillary thyroid cancer patients.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0874.
    PubMed     Abstract available


    May 2021
  4. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    PubMed     Abstract available


    April 2021
  5. LI D, Chi Y, Chen X, Ge MH, et al
    Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
    PubMed     Abstract available


    December 2020
  6. THAKUR S, Daley B, Millo C, Cochran C, et al
    (177)Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-3453.
    PubMed     Abstract available


    November 2020
  7. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    PubMed     Abstract available


    October 2020
  8. WAHDAN-ALASWAD RS, Edgerton SM, Salem H, Kim H, et al
    Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2647.
    PubMed     Abstract available


    September 2020
  9. GRAY KD, McCloskey JE, Vedvyas Y, Kalloo OR, et al
    PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer.
    Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1523.
    PubMed     Abstract available


    April 2020
  10. GHOSH C, Kumar S, Kushchayeva Y, Gaskins K, et al
    A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).
    Clin Cancer Res. 2020;26:2022-2036.
    PubMed     Abstract available


    November 2019
  11. LANDA I, Pozdeyev N, Knauf JA, Haugen BR, et al
    Genetics of Human Thyroid Cancer Cell Lines-Response.
    Clin Cancer Res. 2019;25:6883-6884.
    PubMed    


  12. GARCIA C, Cormier F, Groussin L
    Genetics of Human Thyroid Cancer Cell Lines-Letter.
    Clin Cancer Res. 2019;25:6882.
    PubMed    


  13. WILLIAMS TM
    BRAF(V600E) Inhibitor Radiosensitizes Thyroid Cancer-Response.
    Clin Cancer Res. 2019;25:6557.
    PubMed    


  14. GOTTGENS EL, Rabold K, Span PN
    BRAF(V600E) Inhibitor Radiosensitizes Thyroid Cancer-Letter.
    Clin Cancer Res. 2019;25:6556.
    PubMed    


    September 2019
  15. BROSE MS, Schlumbeger M, Jeffers M, Kappeler C, et al
    Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase 3 DECISION Trial.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-3439.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diseases of the Thyroid is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: